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Abstract  
Introduction: Temozolomide is an alkylating agent used in the treatment of high-grade glioma. Rarely, it can induce an 
aplastic anemia that is usually rapidly fatal if the patient is unable to undergo a bone marrow transplant. This is the first case 
report of a temozolomide-induced aplastic anemia in an anaplastic astrocyoma patient, and of spontaneous complete marrow 
recovery with supportive care. 
Presentation of Case: 21 year old Caucasian female presented with pancytopenia after 39 days of temozolomide at 
75mg/m2/day concurrent with radiation. Hematologic nadir occurred and aplastic anemia was diagnosed 3 months after the 
first dose of temzolomide. She required multiple platelet and red cell transfusions in addition to granulocyte colony 
stimulating factor therapy. During this time, the patient also became pregnant and delivered a healthy baby. With supportive 
care, the patient's white cell count recovered after 6 months, red cell count after 1.5 years, and platelets after 3 years. Her 
tumour remains stable more than 4 years after temozolomide and radiation with no further treatment.  
Conclusions: Aplastic anemia may occur with low-dose temozolomide. Spontaneous marrow recovery using only 
supportive care is possible following temozolomide-induced aplastic anemia. 
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Introduction 
Anaplastic astrocytoma is a malignant, World 
Health Organization grade 3 brain tumour 
composed of astrocytic glial cells. A review of 
1766 anaplastic astrocytoma patients diagnosed 
between 1990-2008 from the Surveillance, 
Epidemiology, and End Results (SEER) database 
identified a median overall survival of 15 months 
[1], although published estimates range from 1-6 
years. Standard treatment includes maximal 
resection and involved-field radiation or clinical 
trial participation. The use of chemotherapy for 
anaplastic astrocytomas is based largely on 
high-grade glioma trials which involved a majority 
of glioblastoma multiforme patients [2]. Initial 
trials employed adjuvant 
procarbazine-lomustine-vincristine (PCV), but the 
regimen's poor tolerability has been a barrier to its 
use. 
Temozolomide (TMZ), an oral alkylating agent, 
has been used instead based on its similar 
theoretical benefit and improved side effect profile 
compared to PCV [3, 4]. Though side effects are 
usually mild, TMZ has been associated with 
thrombocytopenia and other hematologic 
abnormalities. Rarely, TMZ is associated with 
aplastic anemia (AA) and it is even more 
uncommon for patients to regain normal bone 
marrow function following AA. 
We report the case of a 21-year old female with 
anaplastic astrocytoma who experienced 
spontaneous marrow recovery and sustained 
treatment response following TMZ-associated 
aplastic anemia. 
Case presentation 
History and clinical course 
Our patient was a 21 year-old Caucasian female 
who presented to hospital following a generalized 
seizure witnessed by her partner. She had 
experienced occasional seizures and increasing 
headache over the preceding 10 months but had not 
been assessed by a physician. An MRI showed a 
hypointense T1 and hyperintense T2 weighted, 6.5 
x 5.4 x 3.6cm, minimally enhancing lesion with 
right lateral ventricle compression but no midline 
shift. Subtotal resection was completed 7 months 
following presentation. Pathology showed an 
anaplastic astrocytoma with MGMT promoter 
methylation, no loss of heterozygosity of 1p/19q, 
and no classic oligodendroglial features. 
Six weeks after surgery, our patient underwent 
radiation with concurrent TMZ at 75mg/m
2
/day. 
During this phase, she received dapsone for 
Pneumocystis jirovecii prophylaxis and 
ciprofloxacin for leukopenia, but she declined 
anticonvulsant therapy. Thirty-nine days into her 
concurrent treatment, her platelet count fell to 88 
x10
9
 cells/L and TMZ was discontinued. She 
completed radiation therapy with a total dose of 
5940Gy in 33 fractions but was unable to restart 
TMZ due to persistently low blood counts. On the 
last day of radiation, her hemoglobin (Hgb) was 
88g/L, white blood cell (WBC) count 0.7x10
9
 
cells/L, absolute neutrophil count (ANC) 0.5x10
9
 
cells/L, and platelet count (Plt) 49x10
9
 cells/L. 
Despite multiple transfusions, her blood counts 
did not significantly recover. Ten days after the 
conclusion of radiation treatment, she was admitted 
to hospital for four days with febrile neutropenia 
then discharged with levofloxacin and dapsone. 
Most of her counts reached a nadir two weeks later 
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cells/L, and Hgb 97g/L. 
Two weeks after that, she was admitted to 
hospital with another episode of febrile neutropenia 
complicated by Clostridium difficile colitis and Plt 
2x10
9
 cells/L. During this stay, she received 
vancomycin and started G-CSF. Her astrocytoma 
remained stable. She had no other medical 
conditions and was not taking any medications 
other than G-CSF. Vitamin B12, folate, and ferritin 
levels were not drawn; mean corpuscular volume 
and mean corpuscular haemoglobin concentration 
were within normal limits, but her blood smears 
showed 1+ abnormal cells. An attempt at Fanconi 
anemia testing failed due to inadequate cells.  
A bone marrow biopsy performed 3 months 
following the start of her concurrent 
chemoradiation showed marrow cellularity <5%, 
iron stores increased with no sideroblasts, and no 
evidence of neoplasm, blasts, or atypical cells. 
Hematology was therefore consulted about an 
allogeneic bone marrow transplant. A sibling match 
was identified and a date for transplantation was 
arranged. 
After a 3-week stay, she was discharged home 
but received pegfilgrastim 6mg every 2-3 weeks 
with regular outpatient transfusions of irradiated 
packed red blood cells and platelets. Ultimately, 
her bone marrow transplant was cancelled due to 
financial concerns regarding pre-transplant dental 
work. 
Three months later (six months following TMZ 
Day 1), our patient was able to maintain an ANC 
over 1x10
9 
cells/L with once-monthly pegfilgrastim, 
and her RBC transfusion requirements decreased to 
1 unit biweekly. A year after that, she was able to 
discontinue RBC transfusions but continued to 
require multiple units of platelets weekly for 
another 1.5 years despite use of tranexamic acid. 
She developed iron overload from the multiple 
transfusions and was partially compliant with 
desferasirox therapy started in October 2009. It was 
held for about a year from November 2009 during 
her pregnancy; she delivered a healthy baby in 
August 2010. In May 2011 she attempted 
phlebotomy but tolerated it poorly, so continued on 
desferasirox only. 
About 3 years after her first platelet transfusion 
(33 months following TMZ Day 1), our patient 
began to have transfusion reactions. Her platelets 
reached a nadir of 5x10
9
 cells/L despite a normal 
WBC and Hgb, so she was given a single dose of 
IVIg to rule out autoimmune causes. Subsequently, 
her platelet count began to improve and she was 
able to discontinue transfusions. By November 
2012, she became compliant with the desferasirox 
and her ferritin fell from 2329 to 1191. Nearly five 
years after her diagnosis (4 years after 
chemoradiation) and with no additional treatment, 
her tumour remains stable and her hematologic 
abnormalities have resolved aside from slightly low 
platelets (86x10
9 
cells/L in March 2013). 
Discussion 
Hematological abnormalities secondary to TMZ 
are thought to be caused by its alkylating effects. In 
addition, bone marrow precursors may have a 
reduced ability to repair TMZ damage because of 
their relatively low levels of 
O6-methylguanine-DNA methyltransferase 
(MGMT), a DNA repair enzyme that removes 
methyl groups from guanine moieties [4]. 
While severe cytopenias are uncommon, a 
10-year review of the United States' Food and Drug 
Administration (FDA)'s MedWatch adverse event 
database found 39 temozolomide-associated reports 
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of aplastic anemia, and multiple others of 
pancytopenia or marrow aplasia. Eleven aplastic 
anemia incidents were thought to be responsible for 
patient demise [5]. 
Concurrent medications were not described in 
the FDA report, but some medications commonly 
used with temozolomide in brain cancer can also 
affect blood counts. Examples include 
trimethoprim-sulfamethoxazole, dapsone, and 
anticonvulsants. Our patient received dapsone 
during her temozolomide treatment. However, 
dapsone-induced aplastic anemia has been reported 
only rarely in the literature. Of the published cases, 
the clinical onset is 2–12 weeks, and the outcome is 
usually fatal [6, 7]. 
In comparison to the present case, previously 
published reports describe patients with 
glioblastoma, which has an inherently poorer 
prognosis (see Tab 1). Regardless, most patients 
who develop aplastic anemia do not experience 
hematologic recovery and receive only supportive 
care [8-11]. Of those who do recover, some are 
spontaneous but partial [12] while others require a 
bone marrow transplant [13, 14]. Our patient 
received G-CSF and transfusions to maintain her 
counts until full marrow recovery occurred nearly 3 
years after her first dose of temozolomide. Marrow 
recovery time is not well-established, but 
timeframes from 1 week to 6 months have been 
proposed [13, 15]. No significant impact of MGMT 
promoter methylation on recovery time has been 
identified [16]. 
The relationship between temozolomide dose 
and the incidence of aplastic anemia is not clear. 
While myelosuppression usually occurs 21 to 28 
days after the first dose of temozolomide [16], 
some patients do not experience difficulty until 
several adjuvant cycles have been given [11, 15], 
and others never experience dose-limiting 
hematologic toxicity. MGMT-promoter methylated 
tumours [17], certain MGMT polymorphisms [18], 
and female sex have been associated with 
pancytopenia. In men, no corticosteroid use, or 
body surface area (BSA)  greater than 2m
2
, and in 
women, no prior chemotherapy, baseline serum 
creatinine greater than 1mg/dL, baseline platelets 
<270,000/mm
3
, or BSA less than 2m
2 
have also 
been associated with early myelosuppression [19]. 
Our patient, and others whose counts recovered 
following marrow failure, appeared to fare well 
without pursuing further cancer treatment. It is 
tempting to consider a relationship between 
temozolomide response severe enough to require 
bone marrow transplant with overall outcomes. The 
literature is cautionary regarding the use of 
transplant or transfusion to allow more aggressive 
dosing of temozolomide: many of the patients who 
developed aplastic anemia following a 
temozolomide regimen died despite supportive 
transfusions, from development of sepsis [9-11] or 
cancer progression [20]. In addition, while 
alternative dosing regimens have been explored, 
evidence currently indicates that cumulative dose 
and duration of exposure may offer equivalent 
tumour impact and improved hematological 
tolerability compared to using fewer high doses of 
temozolomide. 
A bone marrow transplant was planned for our 
patient after 3 months without marrow recovery. 
However, it was not performed. With supportive 
care only, it was 6 months before our patient's 
neutrophil count remained above 1x10
9
 cells/L, 16 
months before RBC transfusions could be 
discontinued and just over 33 months before 
platelet transfusions were no longer needed. 
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Table 1 AA: anaplastic astrocytoma; Abx: antibiotics; BMT: bone marrow transplant; chg: changed to carbamazepine; d: 
days; D/C: discontinued; Epo: epoetin alfa; G-CSF: granulocyte colony stimulating factor; GBM: glioblastoma 
multiforme; Meds: medication changes; NR: not reported; Plt: platelet transfusion; RBC: red blood cell transfusion; RT: 

























Cases of temozolomide-associated aplastic anemia 
have been previously documented in glioblastoma 
multiforme patients, and full recoveries have 
involved a bone marrow transplant. Our patient had 
anaplastic astrocytoma, and her recovery timeframe 
is longer than described in previous reports. 
However, it demonstrates that complete 
hematological recovery and stable treatment 
response are possible following 
temozolomide-induced aplastic anemia using only 
supportive care. 
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